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Breast cancer is the second most common cancer in women with approximately 522,000 deaths annually worldwide. 
microRNAs have recently been studied as potential biomarkers that regulate gene expression and are involved in 
tumorigenesis. Here we evaluated circulating miR-221 and miR-222 as potential biomarkers for breast cancer by quantitative 
reverse transcription PCR using blood plasma of 30 healthy controls and 30 breast cancer patients. The TNM stage on 
circulating miR-221 and miR-222 was also investigated. Circulating miR-221 and miR-222 were significantly up-regulated 
in breast cancer patients compared to those in healthy controls (P < 0.0022 and P = 0.0058, respectively). Furthermore, 
the relative expression level of circulating miR-221 in patients with stage III breast cancer was higher than in those with 
stage I and II. Taken together, we have shown circulating miR-221 and miR-222 could be useful biomarkers for the 
screening of breast cancer patients. 
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Breast cancer is the most frequently occurring disease in 
females and the second leading cause of death worldwide 
(Siegel et al., 2018). According to the World Health Organ- 
ization (WHO), approximately 522,000 women die each 
year from breast cancer (Ferlay et al., 2015). Current methods 
used to diagnose breast cancer such as mammography, com- 
puted tomography (CT), and magnetic resonance imaging 
(MRI) have been hindered by the cost and expertise needed. 
In addition, tumor serum markers such as carbohydrate 
antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA) 
are nonspecific and have limited sensitivity and specificity 
(Duffy, 1999; Ng et al., 2014). Therefore, it is necessary to 
discover new non-invasive biomarkers for the diagnosis of 
breast cancer. 
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microRNAs are small non-coding RNAs consisting of 
18~25 nucleotides that play a role in regulating gene expres- 
sion by binding the target messenger RNAs (mRNAs). 
Numerous recent studies have reported that microRNAs, 
which are involved in tumorigenesis, are a potential diagnosis, 
prognosis and therapeutic biomarker in various cancers 
(Achkar et al, 2016). miR-221 and miR-222 are located on 
the X chromosome with the same base sequence. Researchers 
have shown that miR-221 and miR-222 are over-expressed 
in breast cancer cells and function as oncomiRNAs (Garofalo 
et al., 2012). Previous studies also show that miR-221/222 
promotes breast cancer cell proliferation, migration, and in- 
vasion by targeting PTEN, a tumor suppressor gene (Li et 
al., 2016). However, the clinical relevance of miR-221/222 
in plasma is still poorly investigated. In this study, circulating 
miR-221 and miR-222 as potential biomarkers for breast 
cancer were investigated using the blood plasma of 30 healthy 
controls and 30 breast cancer patients. 
A total of 30 blood samples were obtained from breast 
cancer patients who had been diagnosed with breast cancer 
at the Yonsei University Severance Hospital, Seoul, Republic 
of Korea from 2000 to 2015. For the healthy controls, a total 
of 30 blood samples were obtained from healthy donors who 
had never been diagnosed with breast cancer. All patients and 
healthy volunteers provided written consent and the study 
was approved by the institutional ethics committee at Yonsei 
University Severance Hospital (approval no. 4-2011-0011) 
and Yonsei University at Wonju (approval no. 1041849- 
201603-BR-010-04). 
For separation of plasma, the whole blood samples were 
centrifuged for 15 min at 600 × g and stored at - 80℃ in 
the deep freezer until use. For extraction of small RNAs 
from the plasma of the study population, the NucleoSpin® 
miRNA Plasma kit (Macherey-Nagel, Düren, Germany) was 
used according to the manufacturer's protocol. 
miRNA expression was quantified by using the TaqMan® 
small RNA assays (Applied Biosystems by Life Technol 
ogies) with miRNA specific primers (miR-221 and miR-222) 
to measure the cycle threshold (CT) - the number of PCR 
cycles in which fluorescence exceeds the background fluores- 
cence value. The samples were repeated twice and the data 
were analyzed using the comparative ΔCT method (2-ΔCT) 
with miR-16 as an endogenous control (Pfaffl et al., 2002). 
We assessed the relative expression level of circulating 
miR-221 and 222 in 30 healthy control and 30 breast cancer 
patients. The characteristics of the patients are shown in Table 
1. The age of the breast cancer patients ranged from 31 to 
76 years old (mean ± SD, 55.03 ± 11.31 years; 95 CI, 
50.73~59.34). Of 30 breast cancer patients, 10 (33.3%) were 
in stage I, followed by 10 (33.3%) in stage II, and 10 (33.3%) 
in stage III. The expression levels of circulating miR-221 
and miR-222 in breast cancer patients were significantly 
higher than those in the healthy controls (P < 0.0022 and P 
= 0.0058, respectively) (Fig. 1). The mean expression levels 
of circulating miR-221 and miR-222 were 0.2569 (range, 
0.0024 to 2.6240) and 0.0562 (range 0.0003 to 0.3530) in 
breast cancer patients and 0.0895 (range, 0.0011 to 0.3184) 
and 0.0230 (range 0.0027 to 0.0641) in healthy controls. The 
area under the ROC curve (AUC) of circulating miR-221 
and miR-222 was 0.7267 (95% CI, 0.5983~0.8551, P = 
0.0025) and 0.7056 (95% CI, 0.5683~0.8428, P = 0.0062), 
respectively. 
Subsequently, the expression levels of circulating miR- 
221 and miR-222 in different stages were analyzed. There 
was a statistically significant difference between the miR- 
221 expression level of stage II and stage III and that of the 
healthy controls (P = 0.0279 for stage II and P = 0.0163 for 
stage III) (Fig. 2A). For miR-222, there also was a significant 
difference between stage II and the healthy controls (P = 
0.0084) (Fig. 2B). 
Many recent studies have reported blood-based biomarkers 
for diagnosing breast cancer, such as circulating tumor cells 
Table 1. Clinical characteristics of breast cancer patients 
 Variable Cases % 
Age   
< 50's  8 26.7 
≥ 50's 21 70.0 
Unknown  1  3.3 
TMN stage   
I 10 33.3 
II 10 33.3 
III 10 33.3 
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Fig. 1. Circulating miR-221, and miR-222 expression level in plasma of breast cancer patients and healthy controls. The relative expression
of miR-221 (A), and miR-222 (B) in plasma of breast cancer patients and healthy controls was analyzed by RT-qPCR. 
Fig. 2. Circulating miR-221, and miR-222 expression level according to TNM stage. The miR-221 (A) and miR-222 (B) expression levels 
were analyzed at different breast cancer stages. 
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(CTCs), circulating tumor DNA (ctDNA), exosomes, and 
microRNAs. Circulating miRNAs have many advantages 
as biomarkers, such as stability during pH changes, freeze- 
thaw cycles, and extended storage (Mitchell et al., 2008; Yu 
et al., 2011). In this study, circulating miR-221 and miR-222 
were potential biomarkers showing 2.87-fold and 2.44-fold 
higher expression for breast cancer patients compared with 
healthy controls, respectively. 
In this study, some healthy controls were shown high 
expression of miR-221 and miR-222 or some patients with 
stage III were shown low expression of miR-221 and miR- 
222. The reason for discrepancies of miR-221 and miR-222 
expression in healthy controls and breast cancer patients was 
that microRNAs regulate multi-genes rather than a single 
gene. For example, miR-221/222 was associated with onco- 
genic process regulating tumor suppressor gene PTEN (Li et 
al., 2016). Also, miR-221/222 was associated with inflam- 
matory immune response regulating peroxisome proliferator- 
activated receptor-γ coactivator-1α (Song et al., 2017). 
There are limitations to our study. First, a small number of 
samples were included. Therefore, it is necessary to conduct 
further research using a larger number of samples from breast 
cancer patients at various stages to demonstrate the utility of 
circulating miR-221 and miR-222 for breast cancer screen- 
ing and diagnosis. Second, we only included breast cancer 
patients with cancer stage I-III. Further study with stage IV 
patients is needed to investigate the expression of circulating 
miR-221 and miR-222 with breast cancer stage IV patients. 
In conclusion, expression levels of miR-221 and miR-222 
in plasma were significantly higher for breast cancer patients 
than for healthy controls. Notably, miR-221 in patients with 
stage III breast cancer was higher than in those with stage I 
and II. Taken together, circulating miR-221 and miR-222 can 
serve as potential non-invasive biomarkers for breast cancer 
screening and diagnosis. 
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